search
Back to results

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

Primary Purpose

Blood Loss

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Hemostatic Matrix
Sponsored by
Hospital for Special Surgery, New York
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Blood Loss focused on measuring To decrease blood loss during knee surgery

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Single Knee replacement for arthritis of the knee

Exclusion Criteria:

  • No inflammatory arthritis (ie. Rheumatoid arthritis)
  • No allergies to cow meat (bovine allergies
  • No history of bleeding disorders

Sites / Locations

  • Hospital for Special Surgery

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Hemostatic Matrix

Control

Arm Description

2 vials of Floseal applied once at the end of surgery

No intervention.

Outcomes

Primary Outcome Measures

Change in Hemoglobin on Day 0 Compared to Preoperatively
Change in Hemoglobin on Day 0 Compared to Preoperatively
Change in Hemoglobin On Day 1 Compared to Preoperatively
Change in Hematocrit on Day 1 Compared to Preoperatively
Change in Hemoglobin on Day 2 Compared to Preoperatively
Change in Hematocrit on Day 2 Compared to Preoperatively
Drain Output
Autologous Amount of Transfusion
Homologous Amount of Transfusion

Secondary Outcome Measures

Range of Motion on Day 3
Visual Analog Pain Scale on Day 3
A VAS is a measurement instrument that tries to measure a characteristic or attitude that cannot easily be measured. The pain VAS scale measures pain intensity on a scale of 0 to 10, with 0=no pain. A higher score indicates greater pain intensity.
Range of Motion at Six Weeks
Visual Analog Pain Scale at 6 Weeks
A VAS is a measurement instrument that tries to measure a characteristic or attitude that cannot easily be measured. The pain VAS scale measures pain intensity on a scale of 0 to 10, with 0=no pain. A higher score indicates greater pain intensity.

Full Information

First Posted
October 5, 2009
Last Updated
November 10, 2017
Sponsor
Hospital for Special Surgery, New York
Collaborators
Baxter Healthcare Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00990288
Brief Title
The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery
Official Title
The Role of a Topical Hemostatic Agent in Reducing Blood Loss in Unilateral Total Knee Arthroplasty
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
August 2010 (Actual)
Study Completion Date
August 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital for Special Surgery, New York
Collaborators
Baxter Healthcare Corporation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine if the agent, Floseal, can decrease the amount of blood patients lose after total knee replacement (TKR) surgery. If this product can be found to have an effect on bleeding, it may potentially reduce the problems associated with bleeding after knee replacement surgery such as pain, stiffness, and the need to have a blood transfusion. The subject's overall participation will be over a period of 6 weeks.
Detailed Description
This is a prospective double blind randomized clinical trial of patients requiring unilateral total knee arthroplasty. The patients will be randomized intra-operatively to receiving Floseal or no treatment. Both the patient and the observers will be blinded to whether the subject received Floseal or no treatment. Only the operating surgeons will be aware of whether Floseal or no treatment was given. As was performed in the pilot study, randomization of Floseal or no treatment will be performed using the sealed envelope technique. Randomization will occur at the time of surgery. The statistician is responsible for maintaining the randomization schedule and issuing the sealed envelopes. The inner envelope will contain whether Floseal or no treatment is to be given on a card which will be counter-signed by the surgeon at the time of surgery. The inner envelope will then be sealed, followed by sealing of the outer envelope. Following the procedure, the surgeon will then take the sealed and signed envelope to surgeon who will store and file it in a locked cabinet in his office. The patients study number will be on the outside surface of the envelopes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Loss
Keywords
To decrease blood loss during knee surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
196 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hemostatic Matrix
Arm Type
Experimental
Arm Description
2 vials of Floseal applied once at the end of surgery
Arm Title
Control
Arm Type
No Intervention
Arm Description
No intervention.
Intervention Type
Drug
Intervention Name(s)
Hemostatic Matrix
Other Intervention Name(s)
"FloSeal", a thrombin and collagen based agent
Intervention Description
FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
Primary Outcome Measure Information:
Title
Change in Hemoglobin on Day 0 Compared to Preoperatively
Time Frame
preoperatively and on the day of surgery
Title
Change in Hemoglobin on Day 0 Compared to Preoperatively
Time Frame
preoperatively and day of surgery
Title
Change in Hemoglobin On Day 1 Compared to Preoperatively
Time Frame
preoperatively and one day after surgery
Title
Change in Hematocrit on Day 1 Compared to Preoperatively
Time Frame
preoperatively and 1 day after surgery
Title
Change in Hemoglobin on Day 2 Compared to Preoperatively
Time Frame
preoperatively and two days after surgery
Title
Change in Hematocrit on Day 2 Compared to Preoperatively
Time Frame
preoperatively and two days after surgery
Title
Drain Output
Time Frame
24 hours postoperatively
Title
Autologous Amount of Transfusion
Time Frame
three days postoperatively
Title
Homologous Amount of Transfusion
Time Frame
three days postoperatively
Secondary Outcome Measure Information:
Title
Range of Motion on Day 3
Time Frame
3days postoperatively
Title
Visual Analog Pain Scale on Day 3
Description
A VAS is a measurement instrument that tries to measure a characteristic or attitude that cannot easily be measured. The pain VAS scale measures pain intensity on a scale of 0 to 10, with 0=no pain. A higher score indicates greater pain intensity.
Time Frame
3 days postoperatively
Title
Range of Motion at Six Weeks
Time Frame
6 weeks postoperatively
Title
Visual Analog Pain Scale at 6 Weeks
Description
A VAS is a measurement instrument that tries to measure a characteristic or attitude that cannot easily be measured. The pain VAS scale measures pain intensity on a scale of 0 to 10, with 0=no pain. A higher score indicates greater pain intensity.
Time Frame
6 weeks postoperatively

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Single Knee replacement for arthritis of the knee Exclusion Criteria: No inflammatory arthritis (ie. Rheumatoid arthritis) No allergies to cow meat (bovine allergies No history of bleeding disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark P Figgie, MD
Organizational Affiliation
Hospital for Special Surgery, New York
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital for Special Surgery
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

We'll reach out to this number within 24 hrs